Menu

The facts on Trichloroethylene

Table of contents

The facts on Trichloroethylene

Last update September 3, 2024

Estimates of current numbers of exposed workers to trichloroethylene (TCE) in the EU are not available. In 1990, 276,000 workers were estimated to be exposed to TCE although uses have significantly decreased since.

When workers are exposed to TCE it is primarily by breathing vapours and through skin contact with vapours or liquid. The substance is classified as Group 1 by IARC, meaning it is carcinogenic to humans. TCE is classified as category 1B carcinogen according to CLP regulation, meaning that the substance may cause cancer in humans. Trichloroethylene causes cancer of the kidney and liver in humans. The substance is possibly mutagenic, and may cause Non-Hodgkin lymphoma.

Where risks occur

The majority of the exposures to TCE occur in industries producing metal products, machinery and transport equipment. In the EU, the use of TCE is only allowed for authorised uses or as an intermediate. It is mostly applied as a solvent to remove grease from metal parts. Due to legislation, the overall volume of TCE used in the EU has declined significantly during the last decades.

More about the substance

TCE is a halogenated alkene that exists at room temperature as a clear, colourless, or blue freely flowing liquid with a pleasant and sweet smell.. It is slightly soluble in water, soluble in ethanol, acetone, diethyl ether, and chloroform, and miscible in oil. It is relatively stable if inhibited, but sunlight, heat, air or oxygen, and moisture can accelerate the reaction to hazardous decomposition products.

How symptoms can affect you

When inhaled, TCE can irritate the nose, eyes and throat and harm the nervous system. The symptoms may include headache, nausea, dizziness, drowsiness and confusion. A severe exposure can also cause unconsciousness. Upon contact with skin, it may cause pain, redness, and swelling of the skin. Prolonged exposure may cause kidney cancer and liver cancer.

The latency period between exposure and TCE related cancer varies from 18 and 34 years.

What you can do

The most effective way to prevent exposure is to substitute with TCE-free or lower-TCE concentration alternative. These substitutes are generally available and must be used. If TCE-containing products cannot be substituted and continued use is granted after an application for authorisation, the exposure to TCE should be reduced through engineering controls such as closed systems or ventilation. Periodically carry out representative exposure measurements so that it is known when action should be taken. Make workers continuously aware of the effects of exposure and encourage them to report early symptoms.. In addition, train workers on hazards, safe work practices and on effective hygiene measures. Supplement this with personal protective equipment (PPE) where feasible controls are not sufficient to reduce exposures below the exposure limits. The PPE can include safety goggles and protective clothing e. g. gloves, aprons and boots. Because TCE ingestion may occur due to skin contamination, skin contact should be prevented as much as possible.

References IARC, CCOHS, NIEHS, NIOSH, EC, REACH

Limit values

EU
Values to be determined (national limits might apply).
 Austria
EU directive
 Belgium
54,7 mg/m3 (TWA)
137 mg/m3 (short term)
Bulgaria
EU directive
Croatia
EU directive
Czech Republic
EU directive
Cyprus
EU directive
Denmark
EU directive
Estonia
EU directive
Finland
EU directive
France
EU directive
Germany
EU directive
Greece
EU directive
Hungary
EU directive
Iceland
EU directive
Ireland
EU directive
Italy
EU directive
Latvia
EU directive
Lithuania
EU directive
Luxembourg
EU directive
Malta
EU directive
Netherlands
8h-TWA = 54.7 mg/m3 (10 ppm)
15min-STEL = 164.1 mg/m3 (30 ppm)
North Macedonia
EU directive
Norway
EU directive
Poland
EU directive
Portugal
EU directive
Romania
EU directive
Serbia
EU directive
Slovakia
EU directive
Slovania
EU directive
Spain
VLA-ED= 10 ppm (54,7 mg/m3)
VLA-EC= 30 (164,1 mg/m3)
Sweden
EU directive
Turkey
EU directive

References: cancer.gov, EFSA, IARC, EC, NIOSH, OSHA, CAREX

Possible substitutions

Please note that this substance or some of it's compounds are listed in Annex XIV (REACH regulation). This substance some of it's compounds are only allowed to be used, imported, or brought into the market, if authorisation requirements of REACH are fulfilled.
Please be aware that for this carcinogen you need to be more cautious when determining potential skin contact and how to regard dermal exposure in your risk reduction strategy.
ECHA registration
CAS number 79-01-6
EC number 201-167-4
Annex VI of CLP 1A
Number of registrations (2023) 1

The European Chemicals Agency (ECHA) works for the safe use of chemicals. It implements the EU’s groundbreaking chemicals legislation, benefiting human health, the environment and innovation and competitiveness in Europe.

GESTIS Database

The data pool may be used for the purpose of occupational health and safety or to obtain information on the hazards posed by chemical substances.

General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Every year, almost 100.000 people die from cancer that was caused by exposure at work
  • Annually more than 100.000 people die because of work-related cancer.
Table of contents